{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:21:18Z","timestamp":1761708078760},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11904-005-0021-7","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T21:11:36Z","timestamp":1180732296000},"page":"68-73","source":"Crossref","is-referenced-by-count":9,"title":["Coronary heart disease in HIV-infected patients"],"prefix":"10.1007","volume":"2","author":[{"given":"Marshall J.","family":"Glesby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"21_CR1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0002-9343(91)80154-E","volume":"90","author":"C Grunfeld","year":"1991","unstructured":"Grunfeld C, Kotler DP, Shigenaga JK, et al.: Circulating interferon-levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991, 90:154\u2013162.","journal-title":"Am J Med"},{"key":"21_CR2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0163-7827(02)00046-2","volume":"42","author":"DY Hui","year":"2003","unstructured":"Hui DY: Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003, 42:81\u201392.","journal-title":"Prog Lipid Res"},{"key":"21_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1371\/journal.pmed.0010019","volume":"1","author":"F Leth van","year":"2004","unstructured":"van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and Efavirenz elicit different changes in lipid profiles in antiretroviral therapy-naive patients infected with HIV-1. Plos Med 2004, 1:19.","journal-title":"Plos Med"},{"key":"21_CR4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","volume":"292","author":"JE Gallant","year":"2004","unstructured":"Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191\u2013201.","journal-title":"JAMA"},{"key":"21_CR5","unstructured":"Currier JS, Boyd F, Kawabata H, et al.: Diabetes mellitus in HIV-infected individuals [abstract]. Proceedings from the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24\u201328, 2002."},{"key":"21_CR6","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200203290-00002","volume":"16","author":"MA Noor","year":"2002","unstructured":"Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-F8.","journal-title":"AIDS"},{"key":"21_CR7","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","volume":"275","author":"H Murata","year":"2000","unstructured":"Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease-inhibitor therapy. J Biol Chem 2000, 275:20251\u201320254.","journal-title":"J Biol Chem"},{"key":"21_CR8","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1097\/00002030-200409030-00017","volume":"18","author":"JM Schwarz","year":"2004","unstructured":"Schwarz JM, Lee GA, Park S, et al.: Indinavir increases glucose production in healthy HIV-negative men. AIDS 2004, 18:1852\u20131854.","journal-title":"AIDS"},{"key":"21_CR9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/hep.20289","volume":"40","author":"AA Butt","year":"2004","unstructured":"Butt AA, Fultz SL, Kwoh CK, et al.: Risk of diabetes in HIV-infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 2004, 40:115\u2013119.","journal-title":"Hepatology"},{"key":"21_CR10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1097\/01.qai.0000137373.26438.18","volume":"37","author":"C Yoon","year":"2004","unstructured":"Yoon C, Gulick RM, Hoover DR, et al.: Case-control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr 2004, 37:1464\u20131469.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"21_CR11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1310\/5E7Q-PGWB-16UE-J48U","volume":"4","author":"DC Chow","year":"2003","unstructured":"Chow DC, Souza SA, Chen R, et al.: Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003, 4:411\u2013416.","journal-title":"HIV Clin Trials"},{"key":"21_CR12","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10096-003-1034-z","volume":"22","author":"BM Bergersen","year":"2003","unstructured":"Bergersen BM, Sandvik L, Dunlop O, et al.: Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003, 22:731\u2013736.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"21_CR13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-200104130-00021","volume":"15","author":"AM Cattelan","year":"2001","unstructured":"Cattelan AM, Trevenzoli M, Sasset L, et al.: Indinavir and systemic hypertension. AIDS 2001, 15:805\u2013807.","journal-title":"AIDS"},{"key":"21_CR14","unstructured":"Hewitt RG, Thompson IV WM, Chu A, et al.: Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy [abstract]. Proceedings from the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Feb 4\u20138, 2001."},{"key":"21_CR15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/135965350300800405","volume":"8","author":"M Araujo de","year":"2003","unstructured":"de Araujo M, Seguro AC: Vasodilator agents protect against indinavir nephrotoxicity. Antivir Ther 2003, 8:295\u2013299.","journal-title":"Antivir Ther"},{"key":"21_CR16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","volume":"32","author":"C Hadigan","year":"2001","unstructured":"Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130\u2013139.","journal-title":"Clin Infect Dis"},{"key":"21_CR17","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/00002030-200110190-00013","volume":"15","author":"FR Sattler","year":"2001","unstructured":"Sattler FR, Qian D, Louie S, et al.: Elevated blood pressure in subjects with lipodystrophy. AIDS 2001, 15:2001\u20132010.","journal-title":"AIDS"},{"key":"21_CR18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/00004872-200307000-00028","volume":"21","author":"C Gazzaruso","year":"2003","unstructured":"Gazzaruso C, Bruno R, Garzaniti A, et al.: Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003, 21:1377\u20131382.","journal-title":"J Hypertens"},{"key":"21_CR19","unstructured":"Henry K, Kitch D, Currier J, et al.: Trends in C-reactive protein levels in a cohort of HIV-1-infected persons durably suppressed on an indinavir-based regimen (ACTG 5056) [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8\u201311, 2004."},{"issue":"23 Suppl1","key":"21_CR20","first-page":"III27","volume":"109","author":"J Davignon","year":"2004","unstructured":"Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109(23 Suppl1):III27-III32.","journal-title":"Circulation"},{"key":"21_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","volume":"104","author":"JH Stein","year":"2001","unstructured":"Stein JH, Klein MA, Bellehumeur JL, et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257\u2013262.","journal-title":"Circulation"},{"key":"21_CR22","unstructured":"Dube MP, Shankar S, Vanderluitgaren JM, et al.: Effect of indinavir (IDV) monotherapy on endothelial function in men without HIV infection [abstract]. Proceedings from the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24\u201328, 2002."},{"key":"21_CR23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0037-1615171","volume":"80","author":"M Karmochkine","year":"1998","unstructured":"Karmochkine M, Ankri A, Calvez V, et al.: Plasma hypercoagulability is correlated to plasma HIV load. Thromb Haemost 1998, 80:208\u2013209.","journal-title":"Thromb Haemost"},{"key":"21_CR24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/jcem.86.2.7410","volume":"86","author":"C Hadigan","year":"2001","unstructured":"Hadigan C, Meigs JB, Rabe J, et al.: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001, 86:939\u2013943.","journal-title":"J Clin Endocrinol Metab"},{"key":"21_CR25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00042560-200204150-00003","volume":"29","author":"K Koppel","year":"2002","unstructured":"Koppel K, Bratt G, Schulman S, et al.: Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitorcontaining highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 29:441\u2013449.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"21_CR26","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/00002030-200105250-00027","volume":"15","author":"E Bernasconi","year":"2001","unstructured":"Bernasconi E, Uhr M, Magenta L, et al.: Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 2001, 15:1081\u20131082.","journal-title":"AIDS"},{"key":"21_CR27","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/01.CIR.0000114520.38748.AA","volume":"109","author":"PY Hsue","year":"2004","unstructured":"Hsue PY, Giri K, Erickson S, et al.: Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004, 109:316\u2013319.","journal-title":"Circulation"},{"key":"21_CR28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.163.4.457","volume":"163","author":"S Matetzky","year":"2003","unstructured":"Matetzky S, Domingo M, Kar S, et al.: Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003, 163:457\u2013460.","journal-title":"Arch Intern Med"},{"key":"21_CR29","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","volume":"349","author":"N Friis-Moller","year":"2003","unstructured":"Friis-Moller N, Sabin CA, Weber R, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003, 349:1993\u20132003. This large, prospective cohort study demonstrated an increased relative risk of myocardial infarction in association with exposure to combination antiretroviral therapy.","journal-title":"N Engl J Med"},{"key":"21_CR30","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","volume":"348","author":"SA Bozzette","year":"2003","unstructured":"Bozzette SA, Ake CF, Tam HK, et al.: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702\u2013710. This large, retrospective analysis of data from the Veterans Administration medical system found that the benefits of antiretroviral therapy on all-cause mortality were not abrogated by large, short-term increases in rates of hospitalization or death from cardiovascular or cerebrovascular causes.","journal-title":"N Engl J Med"},{"issue":"17","key":"21_CR31","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","volume":"17","author":"M Mary-Krause","year":"2003","unstructured":"Mary-Krause M, Cotte L, Simon A, et al.: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17(17):2479\u20132486.","journal-title":"AIDS"},{"key":"21_CR32","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00126334-200208150-00002","volume":"30","author":"D Klein","year":"2002","unstructured":"Klein D, Hurley LB, Quesenberry CPJ, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002, 30:471\u2013477.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"21_CR33","unstructured":"Klein D, Hurley L, Quesenberry C, Sidney S: Hospitalization for coronary heart disease and myocardial infarction among Northern California men with HIV-1 infection: additional follow-up [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8\u201311, 2004."},{"key":"21_CR34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00126334-200308010-00012","volume":"33","author":"JS Currier","year":"2003","unstructured":"Currier JS, Taylor A, Boyd F, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003, 33:506\u2013512.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"21_CR35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"MP Dube","year":"2003","unstructured":"Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613\u2013627. These guidelines provide a sound framework for assessing and managing dyslipidemia in the HIV-infected patient.","journal-title":"Clin Infect Dis"},{"key":"21_CR36","unstructured":"Aberg JA, Zackin RA, Evans SR, et al.: A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: final results of ACTG 5087 [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8\u201311, 2004."},{"key":"21_CR37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","volume":"16","author":"CJ Fichtenbaum","year":"2002","unstructured":"Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. AIDS 2002, 16:569\u2013577.","journal-title":"AIDS"},{"key":"21_CR38","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1128\/AAC.45.12.3445-3450.2001","volume":"45","author":"PH Hsyu","year":"2001","unstructured":"Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al.: Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001, 45:3445\u20133450.","journal-title":"Antimicrob Agents Chemother"},{"key":"21_CR39","unstructured":"Gerber JG, Fichtenbaum CJ, Rosenkranz S, et al.: Efavirenz is a significant inducer of simvastatin and atorvastatin metabolism: results of ACTG A5108 study [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8\u201311, 2004."},{"key":"21_CR40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/422144","volume":"39","author":"MT Gerber","year":"2004","unstructured":"Gerber MT, Mondy KE, Yarasheski KE, et al.: Niacin in HIVinfected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004, 39:419\u2013425.","journal-title":"Clin Infect Dis"},{"key":"21_CR41","unstructured":"Wohl DA, Cunningham C, Tien H-C, et al.: A randomized, open-label clinical trial of omega-3-fatty acid (fish oil) supplementation along with diet and exercise in HIVinfected patients with hypertriglyceridemia [abstract]. Proceedings from the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, Feb 8\u201311, 2004."},{"key":"21_CR42","unstructured":"Fisac C, Fumero E, Crespo M, et al.: Metabolic and body composition changes in patients switching from a protease inhibitor-containing regimen to abacavir (ABC), efavirenz (EFV) or nevirapine (NVP). Twelve-month results of a randomized study (LIPNEFA) [abstract]. Proceedings from the XIV World AIDS Conference, Barcleona, Spain, July 7\u201312, 2002."},{"key":"21_CR43","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/340312","volume":"185","author":"M Opravil","year":"2002","unstructured":"Opravil M, Hirschel B, Lazzarin A, et al.: A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in HIV infection. J Infect Dis 2002, 185:1251\u20131260.","journal-title":"J Infect Dis"},{"key":"21_CR44","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00002030-200108170-00009","volume":"15","author":"N Clumeck","year":"2001","unstructured":"Clumeck N, Goebel F, Rozenbaum W, et al.: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001, 15:1517\u20131526.","journal-title":"AIDS"},{"key":"21_CR45","unstructured":"Murphy R, Pokrovsky V, Rozenbaum W, et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or ATV: 108-week results of BMS study 008\/044 [abstract]. Proceedings from the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feb 10\u201314, 2003."},{"key":"21_CR46","unstructured":"Moreno S, Domingo P, Labarga P, et al.: Dyslipidemia improvement in patients switching from d4T to tenofovir [H-855b]. Proceedings from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Sept 14\u201317, 2003."},{"key":"21_CR47","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/00126334-200308010-00018","volume":"33","author":"A Lafeuillade","year":"2003","unstructured":"Lafeuillade A, Jolly P, Chadapaud S, et al.: Evolution of lipid abnormalities in patients switched from stavudine-to tenofovir-containing regimens. J Acquir Immune Defic Syndr 2003, 33:544\u2013546.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"21_CR48","unstructured":"Glesby MJ, Aberg J, Kendall MS, et al.: Pharmacokinetic (PK) interactions between HIV protease inhibitors (PIs) and calcium channel blockers (CCBs) [abstract ]. Program and Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, Sept 30\u2013Oct 3, 2004."},{"key":"21_CR49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00126334-200403010-00004","volume":"35","author":"DP Kotler","year":"2004","unstructured":"Kotler DP, Muurahainen N, Grunfeld C, et al.: Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 2004, 35:239\u2013252.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-005-0021-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-005-0021-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-005-0021-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:12:58Z","timestamp":1683864778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-005-0021-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s11904-005-0021-7","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}